Table 2 Main results
Author (year) | Country | Population characteristics | Case-finding tool used | Individuals identified with CRD | Confirmed CRD | Prevalence (95% CI) | |||
|---|---|---|---|---|---|---|---|---|---|
NCD included | Individuals screened | Mean age ± SD | Sex male (%) | ||||||
Sharma et al. (2017) | India | End-stage CKD | n = 50 | 45.8 ± 10.0 | n = 32 (64) | Spirometry | n = 44 | Post-dialysis: Restrictive disorder (n = 41)1 Obstructive or mixed disorder (n = 3) 1 | 82% (69.2–90.2) 6% (2-16.2) |
Fernandes et al. (2018) | Brazil | CAD (presence of risk-factor/ investigation) | n = 205 | 64.5 ± 9.82 | n = 113 (55)2 | Spirometry | n = 58 | Persistent obstructive disorder (n = 23) 1 PRISm (n = 35) | 11% (7.5–16.2) 17%(12.5–22.8) |
Martins et al. (2022) | Brazil | Hypertension | n = 1.162 | 62.3 ± 10.1 | n = 378 (32,5) | Spirometry Other tool used CAPTURE CDQ SBQ COPD-SQ Peak flow Microspirometry CAPTURE + Peak flow CDQ + Peak flow SBQ + Peak flow COPD-SQ + Peak flow CAPTURE + Microspirometry CDQ + Microspirometry SBQ + Microspirometry COPD-SQ + Microspirometry | n = 91 n = 48 n = 40 n = 60 n = 62 n = 35 n = 40 n = 25 n = 20 n = 31 n = 31 n = 24 n = 23 n = 32 n = 33 | Asthma (n = 12) Asthma/COPD overlap (n = 19) COPD (n = 60) | 1% (0.59–1.8) 1.6% (1- 2.5) 5.2% (4-6.6) |